Zogenix, Inc. company information, Employees & Contact Information

Transparency notification FMR LLC UCB

HLTH Europe 2025 highlights: How AI, Ecosystems and Evidence are Redefining Healthcare UCB

Digital Care Transformation UCB

It’s More Than Seizures: Understanding Developmental and Epileptic Encephalopathy Disruptions UCB

Transparency notification FMR LLC UCB

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity UCB

Shining a light on myasthenia gravis: UCB marks MG Awareness Month and previews ‘Faces of MG’ UCB

Neurology UCB

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth UCB

UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder PR Newswire

Clinical Studies UCB

Tanner Pharma Group and UCB Pharma Initiate Partnership for Epilepsy Program in Southeast Asia Business Wire

UCB extends its BIMZELX® "Get Yourself Back" direct-to-consumer campaign for the hidradenitis suppurativa community PR Newswire

Partnering UCB

Equity Story UCB

Clinical Studies Index UCB

UCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference PR Newswire

Health of the Planet UCB

UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx) PR Newswire

Conserving water UCB

Driving innovation forward: UCB unveils new R&D facility UCB

Immune to the impossible UCB

Press releases UCB

Ethics and Business Integrity UCB

Transparency notification BlackRock, Inc. UCB

New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference PR Newswire

Transparency notification Goldman Sachs UCB

Transparency notification FMR LLC UCB

Bringing diverse mindsets together to meet patient needs UCB

New insights highlight unmet needs for people living with Lennox-Gastaut syndrome and significant burden of the disease UCB

UCB Half Year Report 2020: UCB’s resilient product portfolio drives continued company growth UCB

Empowering Decisions for Women of Childbearing Age UCB

Epilepsy UCB

UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa PR Newswire

UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting PR Newswire

UCB on Growth Path for a Decade Plus UCB

UCB’s commitment to understanding Sudden Unexpected Death in Epilepsy UCB

Advancing Our Gene Therapy Journey UCB

Transparency notification FMR LLC UCB

World Psoriasis Day 2024: Celebrating the invaluable role of family UCB

Strong Start into UCB’s Decade of Growth UCB

UCB now at the inflection point – ready to start a new phase of growth UCB

UCB Digital Care Transformation (DCTx) Incubator: partnering in innovations that positively benefit patients, society and the world. UCB

Epilepsy New UCB

2021 – Delivering on UCB’s Strategy and Commitments UCB

About UCB UCB

UCB managed 2022 headwinds and is ready for 2023 launches UCB

UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa PR Newswire

UCB's statement on COVID-19 outbreak UCB

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024 Biogen

UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis PR Newswire

UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting PR Newswire

UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024 PR Newswire

UCB and Veeva Collaborate to Advance the Patient Experience in Clinical Trials Veeva

BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis PR Newswire

UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance PR Newswire

UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis PR Newswire

UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis PR Newswire

University of California, Berkeley: Home University of California, Berkeley

Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington's Disease PR Newswire

UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy PR Newswire

UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus Biogen

Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs PR Newswire

UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer's Disease PR Newswire

Lacerta Therapeutics Signs Gene Therapy Research Partnership with UCB Yahoo Finance

UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA® (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn's Disease PR Newswire

UCB Announces availability of NAYZILAM® (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for seizure clusters in the U.S. PR Newswire

UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S. PR Newswire